KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications

키워드

참고문헌 (386)

1. D’Amico G, "Competing risks and prognostic stages of cirrhosis : a 25-year inception cohort study of 494 patients", Aliment Pharmacol Ther, 39, pp.1180~1193 (2014)
2. Kovalak M, "Endoscopic screening for varices in cirrhotic patients : data from a national endoscopic database", Gastrointest Endosc, 65, pp.82~88 (2007)
3. Iwakiri Y, "The hyperdynamic circulation of chronic liver diseases : from the patient to the molecule", Hepatology, 43(2 Suppl 1), pp.S121~S131 (2006)
4. García-Pagán JC, "Functional aspects on the pathophysiology of portal hypertension in cirrhosis", J Hepatol, 57, pp.458~461 (2012)
5. Abraldes JG, "Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state", Am J Physiol Gastrointest Liver Physiol, 290, pp.G980~G987 (2006)
6. Groszmann RJ, "Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis", N Engl J Med, 353, pp.2254~2261 (2005)
7. Merli M, "Incidence and natural history of small esophageal varices in cirrhotic patients", J Hepatol, 38, pp.266~272 (2003)
8. North Italian Endoscopic Club for the Study, "Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study", N Engl J Med, 319, pp.983~989 (1988)
9. McCormick PA, "Improving prognosis following a first variceal haemorrhage over four decades", Gut, 49, pp.682~685 (2001)
10. Carbonell N, "Improved survival after variceal bleeding in patients with cirrhosis over the past two decades", Hepatology, 40, pp.652~659 (2004)
11. Seo YS, "Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage", Hepatology, 60, pp.954~963 (2014)
12. Villanueva C, "A randomized controlled trial comparing ligation and sclerotherapy as emergency endoscopic treatment added to somatostatin in acute variceal bleeding", J Hepatol, 45, pp.560~567 (2006)
13. Reverter E, "A MELD-based model to determine risk of mortality among patients with acute variceal bleeding", Gastroenterology, 146, pp.412~419.e3 (2014)
14. 김영돈, "Changes in the Clinical Outcomes of Variceal Bleeding in Cirrhotic Patients: A 10-Year Experience in Gangwon Province, South Korea", Gut and Liver, 6(4), pp.476~481 (2012), 거트앤리버 소화기연관학회협의회
15. Bosch J, "Prevention of variceal rebleeding", Lancet, 361, pp.952~954 (2003)
16. Bravo AA, "Liver biopsy", N Engl J Med, 344, pp.495~500 (2001)
17. Bedossa P, "Sampling variability of liver fibrosis in chronic hepatitis C", Hepatology, 38, pp.1449~1457 (2003)
18. Regev A, "Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection", Am J Gastroenterol, 97, pp.2614~2618 (2002)
19. "Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group", Hepatology, 20(1 Pt 1), pp.15~20 (1994)
20. Marcellin P, "Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B : a 5-year open-label followup study", Lancet, 381, pp.468~475 (2013)
21. Chang TT, "Longterm entecavir therapy results in the reversal of fibrosis", cirrhosis and continued histological improvement in patients with chronic hepatitis B, 2010, pp.52, 886~893
22. Krogsgaard K, "Correlation between liver morphology and portal pressure in alcoholic liver disease", Hepatology, 4, pp.699~703 (1984)
23. van Leeuwen DJ, "Portal hypertension in chronic hepatitis : relationship to morphological changes", Gut, 31, pp.339~343 (1990)
24. European Association For The Study Of The Liver, "EASL-EORTC clinical practice guidelines : management of hepatocellular carcinoma", J Hepatol, 56, pp.908~943 (2012)
25. Rinella ME, "NAFLD in 2014 : genetics, diagnostics and therapeutic advances in NAFLD", Nat Rev Gastroenterol Hepatol, 12, pp.65~66 (2015)
26. de Franchis R, "Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension", J Hepatol, 63, pp.743~752 (2015)
27. Augustin S, "Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease", Hepatology, 66, pp.1980~1988 (2017)
28. Maurice JB, "Validation of the Baveno VI criteria to identify low risk cirrhotic patients not requiring endoscopic surveillance for varices", J Hepatol, 65, pp.899~905 (2016)
29. Lee HA, "Prediction of the varices needing treatment with non-invasive tests in patients with compensated advanced chronic liver disease", Liver Int, 39, pp.1071~1079 (2019)
30. de Franchis R, "Updating consensus in portal hypertension : report of the Baveno III Consensus Workshop on definitions, methodology and therapeutic strategies in portal hypertension", J Hepatol, 33, pp.846~852 (2000)
31. Grace ND, "Portal hypertension and variceal bleeding : an AASLD single topic symposium", Hepatology, 28, pp.868~880 (1998)
32. de Franchis R, "Definitions, methodology and therapeutic strategies in portal hypertension. A Consensus Development Workshop, Baveno, Lake Maggiore, Italy, April 5 and 6, 1990", J Hepatol, 15, pp.256~261 (1992)
33. Beppu K, "Prediction of variceal hemorrhage by esophageal endoscopy", Gastrointest Endosc, 27, pp.213~218 (1981)
34. Pockros PJ, "Histologic outcomes in hepatitis C-infected patients with varying degrees of virologic response to interferon-based treatments", Hepatology, 52, pp.1193~1200 (2010)
35. Promrat K, "Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis", Hepatology, 51, pp.121~129 (2010)
36. Bruno S, "Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study", Hepatology, 51, pp.2069~2076 (2010)
37. Di Marco V, "Effects of eradicating hepatitis C virus infection in patients with cirrhosis differ with stage of portal hypertension", Gastroenterology, 151, pp.130~139.e2 (2016)
38. D’Ambrosio R, "The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon", ribavirin therapy, 2011, pp.16, 677~684
39. Lens S, "Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis", Gastroenterology, 153, pp.1273~1283.e1 (2017)
40. Merkel C, "A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis", Gastroenterology, 127, pp.476~484 (2004)
41. Sarin SK, "Early primary prophylaxis with beta-blockers does not prevent the growth of small esophageal varices in cirrhosis : a randomized controlled trial", Hepatol Int, 7, pp.248~256 (2013)
42. Qi XS, "Nonselective betablockers in cirrhotic patients with no or small varices : a metaanalysis", World J Gastroenterol, 21, pp.3100~3108 (2015)
43. Bhardwaj A, "Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis : a randomised placebocontrolled trial", Gut, 66, pp.1838~1843 (2017)
44. Kim SG, "A randomized, multi-center, open-label study to evaluate the efficacy of carvedilol vs. propranolol to reduce portal pressure in patients with liver cirrhosis", Am J Gastroenterol, 111, pp.1582~1590 (2016)
45. Garcia-Tsao G, "Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis", Hepatology, 46, pp.922~938 (2007)
46. Zoli M, "Natural history of cirrhotic patients with small esophageal varices : a prospective study", Am J Gastroenterol, 95, pp.503~508 (2000)
47. Garcia-Tsao G, "Portal hypertensive bleeding in cirrhosis : risk stratification, diagnosis, and management : 2016 practice guidance by the American Association for the study of liver diseases", Hepatology, 65, pp.310~335 (2017)
48. D’Amico G, "Pharmacological treatment of portal hypertension : an evidence-based approach", Semin Liver Dis, 19, pp.475~505 (1999)
49. Pagliaro L, "Prevention of first bleeding in cirrhosis. A metaanalysis of randomized trials of nonsurgical treatment", Ann Intern Med, 117, pp.59~70 (1992)
50. Gluud LL, "Banding ligation versus beta-blockers as primary prophylaxis in esophageal varices : systematic review of randomized trials", Am J Gastroenterol, 102, pp.2842~2848 (2007)
51. Li L, "Endoscopic band ligation versus pharmacological therapy for variceal bleeding in cirrhosis : a meta-analysis", Can J Gastroenterol, 25, pp.147~155 (2011)
52. Khuroo MS, "Meta-analysis : endoscopic variceal ligation for primary prophylaxis of oesophageal variceal bleeding", Aliment Pharmacol Ther, 21, pp.347~361 (2005)
53. De BK, "Acute and 7-day portal pressure response to carvedilol and propranolol in cirrhotics", J Gastroenterol Hepatol, 17, pp.183~189 (2002)
54. Bañares R, "Carvedilol, a new nonselective beta-blocker with intrinsic anti-alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis", Hepatology, 30, pp.79~83 (1999)
55. Bañares R, "Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis", Hepatology, 36, pp.1367~1373 (2002)
56. Tripathi D, "Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed", Hepatology, 50, pp.825~833 (2009)
57. Shah HA, "Carvedilol vs. esophageal variceal band ligation in the primary prophylaxis of variceal hemorrhage : a multicentre randomized controlled trial", J Hepatol, 60, pp.757~764 (2014)
58. Abd ElRahim AY, "Efficacy of carvedilol versus propranolol versus variceal band ligation for primary prevention of variceal bleeding", Hepatol Int, 12, pp.75~82 (2018)
59. Sarin SK, "Endoscopic variceal ligation plus propranolol versus endoscopic variceal ligation alone in primary prophylaxis of variceal bleeding", Am J Gastroenterol, 100, pp.797~804 (2005)
60. Bonilha DQ, "Propranolol associated with endoscopic band ligation reduces recurrence of esophageal varices for primary prophylaxis of variceal bleeding : a randomized-controlled trial", Eur J Gastroenterol Hepatol, 27, pp.84~90 (2015)
61. Lo GH, "Controlled trial of ligation plus nadolol versus nadolol alone for the prevention of first variceal bleeding", Hepatology, 52, pp.230~237 (2010)
62. Gheorghe C, "Primary prophylaxis of variceal bleeding in cirrhotics awaiting liver transplantation", Hepatogastroenterology, 53, pp.552~557 (2006)
63. Sharma M, "Comparison of therapies for primary prevention of esophageal variceal bleeding : a systematic review and network meta-analysis", Hepatology, 69, pp.1657~1675 (2019)
64. Angelico M, "Effects of isosorbide-5-mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis", Gastroenterology, 113, pp.1632~1639 (1997)
65. Lui HF, "Primary prophylaxis of variceal hemorrhage : a randomized controlled trial comparing band ligation, propranolol, and isosorbide mononitrate", Gastroenterology, 123, pp.735~744 (2002)
66. García-Pagán JC, "Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed : a double-blind RCT", Hepatology, 37, pp.1260~1266 (2003)
67. Miñano C, "Clinical pharmacology of portal hypertension", Gastroenterol Clin North Am, 39, pp.681~695 (2010)
68. Lebrec D, "Complications of portal hypertension in adults : a French consensus", Eur J Gastroenterol Hepatol, 17, pp.403~410 (2005)
69. Abraczinskas DR, "Propranolol for the prevention of first esophageal variceal hemorrhage : a lifetime commitment?", Hepatology, 34, pp.1096~1102 (2001)
70. Sersté T, "Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites", Hepatology, 52, pp.1017~1022 (2010)
71. Sersté T, "Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites : a cross-over study", J Hepatol, 55, pp.794~799 (2011)
72. Mandorfer M, "Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis", Gastroenterology, 146, pp.1680~1690 (2014)
73. Leithead JA, "Non-selective β-blockers are associated with improved survival in patients with ascites listed for liver transplantation", Gut, 64, pp.1111~1119 (2015)
74. Bossen L, "Nonselective β-blockers do not affect mortality in cirrhosis patients with ascites : post Hoc analysis of three randomized controlled trials with 1198patients", Hepatology, 63, pp.1968~1976 (2016)
75. Madsen BS, "Keep the sick from harm in spontaneous bacterial peritonitis : dose of beta blockers matters", J Hepatol, 64, pp.1455~1456 (2016)
76. Shaheen NJ, "Pantoprazole reduces the size of postbanding ulcers after variceal band ligation : a randomized, controlled trial", Hepatology, 41, pp.588~594 (2005)
77. 부귀범, "식도정맥류 밴드결찰술 후 궤양 치유에 대한 양성자 펌프 억제제의 효과", 대한소화기학회지, 51(4), pp.232~240 (2008), 대한소화기학회
78. Kang SH, "Proton pump inhibitor therapy is associated with reduction of early bleeding risk after prophylactic endoscopic variceal band ligation: a retrospective cohort study", Medicine(Baltimore), 95, pp.e2903~ (2016)
79. Dam G, "Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites", Hepatology, 64, pp.1265~1272 (2016)
80. Tsai CF, "Proton pump inhibitors increase risk for hepatic encephalopathy in patients with cirrhosis in a population study", Gastroenterology, 152, pp.134~141 (2017)
81. Goel GA, "Increased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic acid suppression", Clin Gastroenterol Hepatol, 10, pp.422~427 (2012)
82. Hwang JH, "The role of endoscopy in the management of variceal hemorrhage", Gastrointest Endosc, 80, pp.221~227 (2014)
83. Villanueva C, "Transfusion strategies for acute upper gastrointestinal bleeding", N Engl J Med, 368, pp.11~21 (2013)
84. Castaneda B, "Effects of blood volume restitution following a portal hypertensive-related bleeding in anesthetized cirrhotic rats", Hepatology, 33, pp.821~825 (2001)
85. Bosch J, "Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis : a randomized, double-blind trial", Gastroenterology, 127, pp.1123~1130 (2004)
86. Bosch J, "Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis : a randomized, controlled trial", Hepatology, 47, pp.1604~1614 (2008)
87. Bernard B, "Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding : a meta-analysis", Hepatology, 29, pp.1655~1661 (1999)
88. Chavez-Tapia NC, "Meta-analysis : antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding-an updated Cochrane review", Aliment Pharmacol Ther, 34, pp.509~518 (2011)
89. Tandon P, "Risk of bacterial infection in patients with cirrhosis and acute variceal hemorrhage, based on Child-Pugh class, and effects of antibiotics", Clin Gastroenterol Hepatol, 13, pp.1189~1196.e2 (2015)
90. Fernández J, "Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage", Gastroenterology, 131, pp.1049~1056 (2006)
91. Wells M, "Meta-analysis : vasoactive medications for the management of acute variceal bleeds", Aliment Pharmacol Ther, 35, pp.1267~1278 (2012)
92. Ioannou G, "Terlipressin for acute esophageal variceal hemorrhage", Cochrane Database Syst Rev, (1), pp.CD002147~ (2003)
93. Suk KT, "Revision and update on clinical practice guideline for liver cirrhosis", Korean J Hepatol, 18, pp.1~21 (2012)
94. Solà E, "Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension", Hepatology, 52, pp.1783~1790 (2010)
95. Hashizume M, "Endoscopic ligation of esophageal varices compared with injection sclerotherapy : a prospective randomized trial", Gastrointest Endosc, 39, pp.123~126 (1993)
96. Lo GH, "A prospective, randomized trial of sclerotherapy versus ligation in the management of bleeding esophageal varices", Hepatology, 22, pp.466~471 (1995)
97. Laine L, "Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding. A meta-analysis", Ann Intern Med, 123, pp.280~287 (1995)
98. Lo GH, "Emergency banding ligation versus sclerotherapy for the control of active bleeding from esophageal varices", Hepatology, 25, pp.1101~1104 (1997)
99. Stiegmann GV, "Endoscopic sclerotherapy as compared with endoscopic ligation for bleeding esophageal varices", N Engl J Med, 326, pp.1527~1532 (1992)
100. Dai C, "Endoscopic variceal ligation compared with endoscopic injection sclerotherapy for treatment of esophageal variceal hemorrhage : a meta-analysis", World J Gastroenterol, 21, pp.2534~2541 (2015)
101. Hsu YC, "Delayed endoscopy as a risk factor for in-hospital mortality in cirrhotic patients with acute variceal hemorrhage", J Gastroenterol Hepatol, 24, pp.1294~1299 (2009)
102. Chen PH, "Delayed endoscopy increases re-bleeding and mortality in patients with hematemesis and active esophageal variceal bleeding : a cohort study", J Hepatol, 57, pp.1207~1213 (2012)
103. Monescillo A, "Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding", Hepatology, 40, pp.793~801 (2004)
104. García-Pagán JC, "Early use of TIPS in patients with cirrhosis and variceal bleeding", N Engl J Med, 362, pp.2370~2379 (2010)
105. Rudler M, "Early-TIPSS placement prevents rebleeding in high-risk patients with variceal bleeding, without improving survival", Aliment Pharmacol Ther, 40, pp.1074~1080 (2014)
106. Ibrahim M, "Early application of haemostatic powder added to standard management for oesophagogastric variceal bleeding : a randomised trial", Gut, 68, pp.844~853 (2019)
107. de Franchis R, "Revising consensus in portal hypertension:report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension", J Hepatol, 53, pp.762~768 (2010)
108. Azoulay D, "Salvage transjugular intrahepatic portosystemic shunt for uncontrolled variceal bleeding in patients with decompensated cirrhosis", J Hepatol, 35, pp.590~597 (2001)
109. Panés J, "Efficacy of balloon tamponade in treatment of bleeding gastric and esophageal varices. Results in 151 consecutive episodes", Dig Dis Sci, 33, pp.454~459 (1988)
110. Terés J, "Esophageal tamponade for bleeding varices. Controlled trial between the Sengstaken-Blakemore tube and the Linton-Nachlas tube", Gastroenterology, 75, pp.566~569 (1978)
111. Haq I, "Recent advances in the management of variceal bleeding", Gastroenterol Rep(Oxf), 5, pp.113~126 (2017)
112. Escorsell À, "Esophageal balloon tamponade versus esophageal stent in controlling acute refractory variceal bleeding : a multicenter randomized, controlled trial", Hepatology, 63, pp.1957~1967 (2016)
113. Lebrec D, "A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis : a final report", Hepatology, 4, pp.355~358 (1984)
114. Garden OJ, "Propranolol in the prevention of recurrent variceal hemorrhage in cirrhotic patients. A controlled trial", Gastroenterology, 98, pp.185~190 (1990)
115. Colombo M, "Beta-blockade prevents recurrent gastrointestinal bleeding in well-compensated patients with alcoholic cirrhosis : a multicenter randomized controlled trial", Hepatology, 9, pp.433~438 (1989)
116. García-Pagán JC, "Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study", Ann Intern Med, 114, pp.869~873 (1991)
117. Gournay J, "Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding", Hepatology, 31, pp.1239~1245 (2000)
118. Cheung J, "Systematic review : secondary prevention with band ligation, pharmacotherapy or combination therapy after bleeding from oesophageal varices", Aliment Pharmacol Ther, 30, pp.577~588 (2009)
119. Ding SH, "Efficacy of beta-adrenergic blocker plus 5-isosorbide mononitrate and endoscopic band ligation for prophylaxis of esophageal variceal rebleeding : a meta-analysis", World J Gastroenterol, 15, pp.2151~2155 (2009)
120. Lo GH, "Improved survival in patients receiving medical therapy as compared with banding ligation for the prevention of esophageal variceal rebleeding", Hepatology, 48, pp.580~587 (2008)
121. Lo GH, "Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding : a prospective, randomized trial", Hepatology, 32, pp.461~465 (2000)
122. de la Peña J, "Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding : a multicenter trial", Hepatology, 41, pp.572~578 (2005)
123. Gonzalez R, "Meta-analysis : combination endoscopic and drug therapy to prevent variceal rebleeding in cirrhosis", Ann Intern Med, 149, pp.109~122 (2008)
124. Ravipati M, "Pharmacotherapy plus endoscopic intervention is more effective than pharmacotherapy or endoscopy alone in the secondary prevention of esophageal variceal bleeding : a meta-analysis of randomized, controlled trials", Gastrointest Endosc, 70, pp.658~664. e5 (2009)
125. Puente A, "Drugs plus ligation to prevent rebleeding in cirrhosis : an updated systematic review", Liver Int, 34, pp.823~833 (2014)
126. Stanley AJ, "Multicentre randomised controlled study comparing carvedilol with variceal band ligation in the prevention of variceal rebleeding", J Hepatol, 61, pp.1014~1019 (2014)
127. Lo GH, "Randomized, controlled trial of carvedilol versus nadolol plus isosorbide mononitrate for the prevention of variceal rebleeding", J Gastroenterol Hepatol, 27, pp.1681~1687 (2012)
128. D’Amico G, "Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis : a systematic review", Gastroenterology, 131, pp.1611~1624 (2006)
129. Sauerbruch T, "Prevention of rebleeding from esophageal varices in patients with cirrhosis receiving small-diameter stents versus hemodynamically controlled medical therapy", Gastroenterology, 149, pp.660~668.e1 (2015)
130. Holster IL, "Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + β-blocker for prevention of variceal rebleeding", Hepatology, 63, pp.581~589 (2016)
131. Boyer TD, "The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension", Hepatology, 41, pp.386~400 (2005)
132. Henderson JM, "Salvage therapies for refractory variceal hemorrhage", Clin Liver Dis, 5, pp.709~725 (2001)
133. Kawaoka T, "Beneficial effects of living-donor liver transplantation on esophageal varices", J Gastroenterol, 43, pp.982~989 (2008)
134. Sarin SK, "Prevalence, classification and natural history of gastric varices : a longterm follow-up study in 568 portal hypertension patients", Hepatology, 16, pp.1343~1349 (1992)
135. de Franchis R, "Natural history of portal hypertension in patients with cirrhosis", Clin Liver Dis, 5, pp.645~663 (2001)
136. Sarin SK, "Long-term follow-up of gastric variceal sclerotherapy : an eleven-year experience", Gastrointest Endosc, 46, pp.8~14 (1997)
137. Kim T, "Risk factors for hemorrhage from gastric fundal varices", Hepatology, 25, pp.307~312 (1997)
138. 이충현, "위정맥류의 자연경과와 출혈의 위험인자", Clinical and Molecular Hepatology, 14(3), pp.331~341 (2008), 대한간학회
139. Jakab SS, "Screening and surveillance of varices in patients with cirrhosis", Clin Gastroenterol Hepatol, 17, pp.26~29 (2019)
140. Park SW, "Changes in cardiac varices and their clinical significance after eradication of esophageal varices by band ligation", Can J Gastroenterol Hepatol, 2016, pp.2198163~ (2016)
141. Mishra SR, "Primary prophylaxis of gastric variceal bleeding comparing cyanoacrylate injection and beta-blockers : a randomized controlled trial", J Hepatol, 54, pp.1161~1167 (2011)
142. Park JK, "Balloon-occluded retrograde transvenous obliteration(BRTO)for treatment of gastric varices : review and meta-analysis", Dig Dis Sci, 60, pp.1543~1553 (2015)
143. Gwon DI, "Gastric varices and hepatic encephalopathy : treatment with vascular plug and gelatin sponge-assisted retrograde transvenous obliteration--a primary report", Radiology, 268, pp.281~287 (2013)
144. Gwon DI, "Vascular plug-assisted retrograde transvenous obliteration for the treatment of gastric varices and hepatic encephalopathy : a prospective multicenter study", J Vasc Interv Radiol, 26, pp.1589~1595 (2015)
145. Ryan BM, "A pathophysiologic, gastroenterologic, and radiologic approach to the management of gastric varices", Gastroenterology, 126, pp.1175~1189 (2004)
146. Thakeb F, "Endoscopic diagnosis of gastric varices", Endoscopy, 26, pp.287~291 (1994)
147. Tripathi D, "U. K. guidelines on the management of variceal haemorrhage in cirrhotic patients", Gut, 64, pp.1680~1704 (2015)
148. Kapoor A, "Endoscopic diagnosis and therapy in gastroesophageal variceal bleeding", Gastrointest Endosc Clin N Am, 25, pp.491~507 (2015)
149. Akahoshi T, "Long-term results of endoscopic Histoacryl injection sclerotherapy for gastric variceal bleeding : a 10-year experience", Surgery, 131(1 Suppl), pp.S176~S181 (2002)
150. 김재우, "위정맥류 출혈 환자에서 N-butyl-2-cyanoacrylate를 이용한 내시경경화요법의 치료 효과", Clinical and Molecular Hepatology, 12(3), pp.394~403 (2006), 대한간학회
151. Paik CN, "The therapeutic effect of cyanoacrylate on gastric variceal bleeding and factors related to clinical outcome", J Clin Gastroenterol, 42, pp.916~922 (2008)
152. 전정환, "Clinical outcomes of gastric variceal obliteration using N-butyl-2-cyanoacrylate in patients with acute gastric variceal hemorrhage", The Korean Journal of Internal Medicine, 29(4), pp.437~444 (2014), 대한내과학회[DOI]
153. Lee HA, "Prognosis of patients with gastric variceal bleeding after endoscopic variceal obturation according to the type of varices", Eur J Gastroenterol Hepatol, 31, pp.211~217 (2019)
154. Yeon Seok Seo, "Prevention and management of gastroesophageal varices", Clinical and Molecular Hepatology, 24(1), pp.20~42 (2018), 대한간학회
155. Tan PC, "A randomized trial of endoscopic treatment of acute gastric variceal hemorrhage : N-butyl-2-cyanoacrylate injection versus band ligation", Hepatology, 43, pp.690~697 (2006)
156. El Amin H, "A randomized trial of endoscopic variceal ligation versus cyanoacrylate injection for treatment of bleeding junctional varices", Trop Gastroenterol, 31, pp.279~284 (2010)
157. Lo GH, "A retrospective comparative study of histoacryl injection and banding ligation in the treatment of acute type 1 gastric variceal hemorrhage", Scand J Gastroenterol, 48, pp.1198~1204 (2013)
158. Cales P, "Early administration of vapreotide for variceal bleeding in patients with cirrhosis", N Engl J Med, 344, pp.23~28 (2001)
159. Lo GH, "Is endoscopic ligation therapy with large detachable snares and elastic bands really safe and effective?", Gastrointest Endosc, 57, pp.438~439 (2003)
160. Mahadeva S, "Costeffectiveness of N-butyl-2-cyanoacrylate(histoacryl)glue injections versus transjugular intrahepatic portosystemic shunt in the management of acute gastric variceal bleeding", Am J Gastroenterol, 98, pp.2688~2693 (2003)
161. Procaccini NJ, "Endoscopic cyanoacrylate versus transjugular intrahepatic portosystemic shunt for gastric variceal bleeding : a single-center U. S. analysis", Gastrointest Endosc, 70, pp.881~887 (2009)
162. Chau TN, "“Salvage” transjugular intrahepatic portosystemic shunts: gastric fundal compared with esophageal variceal bleeding", Gastroenterology, 114, pp.981~987 (1998)
163. Barange K, "Transjugular intrahepatic portosystemic shunt in the treatment of refractory bleeding from ruptured gastric varices", Hepatology, 30, pp.1139~1143 (1999)
164. Sahagun G, "Outcome of 100 patients after transjugular intrahepatic portosystemic shunt for variceal hemorrhage", Am J Gastroenterol, 92, pp.1444~1452 (1997)
165. Sanyal AJ, "Transjugular intrahepatic portosystemic shunts for patients with active variceal hemorrhage unresponsive to sclerotherapy", Gastroenterology, 111, pp.138~146 (1996)
166. Stanley AJ, "A comparison between gastric and oesophageal variceal haemorrhage treated with transjugular intrahepatic portosystemic stent shunt(TIPSS)", Aliment Pharmacol Ther, 11, pp.171~176 (1997)
167. Barrio J, "Comparison of transjugular intrahepatic portosystemic shunt dysfunction in PTFE-covered stent-grafts versus bare stents", Eur J Radiol, 55, pp.120~124 (2005)
168. Wang Q, "Eight millimetre covered TIPS does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleeding", J Hepatol, 67, pp.508~516 (2017)
169. Colombato L, "The role of transjugular intrahepatic portosystemic shunt(TIPS)in the management of portal hypertension", J Clin Gastroenterol, 41(Suppl 3), pp.S344~S351 (2007)
170. Kanagawa H, "Treatment of gastric fundal varices by balloon-occluded retrograde transvenous obliteration", J Gastroenterol Hepatol, 11, pp.51~58 (1996)
171. Chu HH, "Long-term outcomes of balloon-occluded retrograde transvenous obliteration for the treatment of gastric varices : a comparison of ethanolamine oleate and sodium tetradecyl sulfate", Cardiovasc Intervent Radiol, 41, pp.578~586 (2018)
172. Imai Y, "Long-term outcome of 154 patients receiving balloon-occluded retrograde transvenous obliteration for gastric fundal varices", J Gastroenterol Hepatol, 31, pp.1844~1850 (2016)
173. 장세영, "Clinical outcomes of balloon-occluded retrograde transvenous obliteration for the treatment of gastric variceal hemorrhage in Korean patients with liver cirrhosis: a retrospective multicenter study", Clinical and Molecular Hepatology, 18(4), pp.368~374 (2012), 대한간학회[DOI]
174. Chavez-Tapia NC, "Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding", Cochrane Database Syst Rev, (9), pp.CD002907~ (2010)
175. Besson I, "Sclerotherapy with or without octreotide for acute variceal bleeding", N Engl J Med, 333, pp.555~560 (1995)
176. Zuberi BF, "Comparison of endoscopic variceal sclerotherapy alone and in combination with octreotide in controlling acute variceal hemorrhage and early rebleeding in patients with low-risk cirrhosis", Am J Gastroenterol, 95, pp.768~771 (2000)
177. Henry Z, "Gastric and ectopic varices", Clin Liver Dis, 18, pp.371~388 (2014)
178. Ríos Castellanos E, "Endoscopic injection of cyanoacrylate glue versus other endoscopic procedures for acute bleeding gastric varices in people with portal hypertension", Cochrane Database Syst Rev, (5), pp.CD010180~ (2015)
179. Watanabe K, "Portal hemodynamics in patients with gastric varices. A study in 230patients with esophageal and", or gastric varices using portal vein catheterization, 1988, pp.95, 434~440
180. Saad WE, "Vascular anatomy and the morphologic and hemodynamic classifications of gastric varices and spontaneous portosystemic shunts relevant to the BRTO procedure", Tech Vasc Interv Radiol, 16, pp.60~100 (2013)
181. Maruyama H, "Hemodynamic features of gastrorenal shunt : a Doppler study in cirrhotic patients with gastric fundal varices", Acad Radiol, 15, pp.1148~1154 (2008)
182. 김문영, "Clinical features and outcomes of gastric variceal bleeding: retrospective Korean multicenter data", Clinical and Molecular Hepatology, 19(1), pp.36~44 (2013), 대한간학회[DOI]
183. Qiao W, "Cyanoacrylate injection versus band ligation in the endoscopic management of acute gastric variceal bleeding: meta-analysis of randomized, controlled studies based on the PRISMA statement", Medicine (Baltimore), 94, pp.e1725~ (2015)
184. 최영호, "Balloon-Occluded Retrograde Transvenous Obliteration for Gastric Variceal Bleeding:Its Feasibility Compared with Transjugular Intrahepatic Portosystemic Shunt", Korean Journal of Radiology, 4(2), pp.6~116 (2003), 대한영상의학회
185. Sabri SS, "Short-term rebleeding rates for isolated gastric varices managed by transjugular intrahepatic portosystemic shunt versus balloon-occluded retrograde transvenous obliteration", J Vasc Interv Radiol, 25, pp.355~361 (2014)
186. Wang YB, "Balloon-occluded retrograde transvenous obliteration versus transjugular intrahepatic portosystemic shunt for treatment of gastric varices due to portal hypertension : a meta-analysis", J Gastroenterol Hepatol, 31, pp.727~733 (2016)
187. Geunwu Gimm, "Balloon-Occluded Retrograde Transvenous Obliteration versus Transjugular Intrahepatic Portosystemic Shunt for the Management of Gastric Variceal Bleeding", Gut and Liver, 12(6), pp.704~713 (2018), 거트앤리버 소화기연관학회협의회
188. Hong CH, "Treatment of patients with gastric variceal hemorrhage : endoscopic Nbutyl-2-cyanoacrylate injection versus balloon-occluded retrograde transvenous obliteration", J Gastroenterol Hepatol, 24, pp.372~378 (2009)
189. 김가람, "Can proton pump inhibitors reduce rebleeding following Histoacryl sclerotherapy for gastric variceal hemorrhage?", The Korean Journal of Internal Medicine, 30(5), pp.593~601 (2015), 대한내과학회[DOI]
190. Lo GH, "A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding", Endoscopy, 39, pp.679~685 (2007)
191. Ninoi T, "Balloon-occluded retrograde transvenous obliteration of gastric varices with gastrorenal shunt : long-term follow-up in 78 patients", AJR Am J Roentgenol, 184, pp.1340~1346 (2005)
192. Wu CY, "Pharmacologic efficacy in gastric variceal rebleeding and survival : including multivariate analysis", J Clin Gastroenterol, 35, pp.127~132 (2002)
193. Mishra SR, "Endoscopic cyanoacrylate injection versus beta-blocker for secondary prophylaxis of gastric variceal bleed : a randomised controlled trial", Gut, 59, pp.729~735 (2010)
194. Hung HH, "Efficacy of non-selective β-blockers as adjunct to endoscopic prophylactic treatment for gastric variceal bleeding : a randomized controlled trial", J Hepatol, 56, pp.1025~1032 (2012)
195. Norton ID, "Management of ectopic varices", Hepatology, 28, pp.1154~1158 (1998)
196. Primignani M, "Natural history of portal hypertensive gastropathy in patients with liver cirrhosis. The New Italian Endoscopic Club for the study and treatment of esophageal varices(NIEC)", Gastroenterology, 119, pp.181~187 (2000)
197. D’Amico G, "Natural history of congestive gastropathy in cirrhosis. The Liver Study Group of V. Cervello Hospital", Gastroenterology, 99, pp.1558~1564 (1990)
198. Spina GP, "Gastric endoscopic features in portal hypertension : final report of a consensus conference, Milan, Italy, September 19, 1992", J Hepatol, 21, pp.461~467 (1994)
199. Zardi EM, "Portal hypertensive gastropathy in cirrhotics without varices : a case-control study", Eur J Gastroenterol Hepatol, 27, pp.91~96 (2015)
200. 최원혁, "문맥압항진 위병증과 위전정부 혈관확장증", 대한소화기학회지, 56(3), pp.186~191 (2010), 대한소화기학회
201. Kim MY, "Portal hypertensive gastropathy : correlation with portal hypertension and prognosis in cirrhosis", Dig Dis Sci, 55, pp.3561~3567 (2010)
202. Patwardhan VR, "Review article : the management of portal hypertensive gastropathy and gastric antral vascular ectasia in cirrhosis", Aliment Pharmacol Ther, 40, pp.354~362 (2014)
203. Zhou Y, "Comparison of the efficacy of octreotide, vasopressin, and omeprazole in the control of acute bleeding in patients with portal hypertensive gastropathy : a controlled study", J Gastroenterol Hepatol, 17, pp.973~979 (2002)
204. Kamath PS, "Gastric mucosal responses to intrahepatic portosystemic shunting in patients with cirrhosis", Gastroenterology, 118, pp.905~911 (2000)
205. Pérez-Ayuso RM, "Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis", Lancet, 337, pp.1431~1434 (1991)
206. Jepsen P, "Clinical course of alcoholic liver cirrhosis : a Danish population-based cohort study", Hepatology, 51, pp.1675~1682 (2010)
207. Blei AT, "Hepatic Encephalopathy", Am J Gastroenterol, 96, pp.1968~1976 (2001)
208. Ferenci P, "Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification : final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998", Hepatology, 35, pp.716~721 (2002)
209. Vilstrup H, "Hepatic encephalopathy in chronic liver disease : 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver", Hepatology, 60, pp.715~735 (2014)
210. Bajaj JS, "Review article : the design of clinical trials in hepatic encephalopathy--an International Society for Hepatic Encephalopathy and Nitrogen Metabolism(ISHEN)consensus statement", Aliment Pharmacol Ther, 33, pp.739~747 (2011)
211. Saunders JB, "A 20-year prospective study of cirrhosis", Br Med J(Clin Res Ed), 282, pp.263~266 (1981)
212. Jang JW, "Effects of virologic response to treatment on short-and long-term outcomes of patients with chronic hepatitis B virus infection and decompensated cirrhosis", Clin Gastroenterol Hepatol, 16, pp.1954~1963 (2018)
213. Jeong JH, "CLIFSOFA score and SIRS are independent prognostic factors in patients with hepatic encephalopathy due to alcoholic liver cirrhosis", Medicine(Baltimore), 95, pp.e3935~ (2016)
214. Labenz C, "Prospective evaluation of the impact of covert hepatic encephalopathy on quality of life and sleep in cirrhotic patients", Aliment Pharmacol Ther, 48, pp.313~321 (2018)
215. Delanty N, "Status epilepticus arising de novo in hospitalized patients : an analysis of 41patients", Seizure, 10, pp.116~119 (2001)
216. Prabhakar S, "Management of agitation and convulsions in hepatic encephalopathy", Indian J Gastroenterol, 22(Suppl 2), pp.S54~S58 (2003)
217. Ferenci P, "Newer approaches to therapy of hepatic encephalopathy", Semin Liver Dis, 16, pp.329~338 (1996)
218. Bajaj JS, "Spectrum of neurocognitive impairment in cirrhosis : implications for the assessment of hepatic encephalopathy", Hepatology, 50, pp.2014~2021 (2009)
219. Wijdicks EF, "Hepatic encephalopathy", N Engl J Med, 375, pp.1660~1670 (2016)
220. Krieger D, "Manganese and chronic hepatic encephalopathy", Lancet, 346, pp.270~274 (1995)
221. Davidson EA, "The differentiation of delirium tremens from impending hepatic coma", J Ment Sci, 104, pp.326~333 (1958)
222. James IM, "Effect of induced metabolic alkalosis in hepatic encephalopathy", Lancet, 2, pp.1106~1108 (1969)
223. Yun BC, "Hyponatremia in hepatic encephalopathy : an accomplice or innocent bystander?", Am J Gastroenterol, 104, pp.1390~1391 (2009)
224. Ito S, "Senile portosystemic hepatic encephalopathy as a treatable dementia-like syndrome", J Neurol, 251, pp.1015~1016 (2004)
225. Sutter R, "Uncovering clinical and radiological associations of triphasic waves in acute encephalopathy : a case-control study", Eur J Neurol, 21, pp.660~666 (2014)
226. Romero-Gómez M, "Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy", Am J Gastroenterol, 96, pp.2718~2723 (2001)
227. Amodio P, "Clinical neurophysiology of hepatic encephalopathy", J Clin Exp Hepatol, 5(Suppl 1), pp.S60~S68 (2015)
228. Van der Rijt CC, "Objective measurement of hepatic encephalopathy by means of automated EEG analysis", Electroencephalogr Clin Neurophysiol, 57, pp.423~426 (1984)
229. Marchetti P, "Electroencephalography in patients with cirrhosis", Gastroenterology, 141, pp.1680~1689.e1-e2 (2011)
230. Ficker DM, "Epileptiform abnormalities in hepatic encephalopathy", J Clin Neurophysiol, 14, pp.230~234 (1997)
231. Olesen SS, "Electroencephalogram variability in patients with cirrhosis associates with the presence and severity of hepatic encephalopathy", J Hepatol, 65, pp.517~523 (2016)
232. Sawhney IM, "Visual and auditory evoked responses in acute severe hepatitis", J Gastroenterol Hepatol, 12, pp.554~559 (1997)
233. Moon JH, "Prolonged N200 is the early neurophysiologic change in the patient with minimal hepatic encephalopathy", Scand J Gastroenterol, 49, pp.604~610 (2014)
234. Lockwood AH, "Blood ammonia levels and hepatic encephalopathy", Metab Brain Dis, 19, pp.345~349 (2004)
235. Tapper EB, "Refining the ammonia hypothesis : a physiology-driven approach to the treatment of hepatic encephalopathy", Mayo Clin Proc, 90, pp.646~658 (2015)
236. Rose CF, "Ammonia-lowering strategies for the treatment of hepatic encephalopathy", Clin Pharmacol Ther, 92, pp.321~331 (2012)
237. Kramer L, "Partial pressure of ammonia versus ammonia in hepatic encephalopathy", Hepatology, 31, pp.30~34 (2000)
238. Saleh A, "Serum levels of astroglial S100-beta and neuron-specific enolase in hepatic encephalopathy patients", East Mediterr Health J, 13, pp.1114~1123 (2007)
239. Fessel JM, "Analysis of the causes and prevention of hepatic coma", Gastroenterology, 62, pp.191~ (1972)
240. Acharya C, "Current management of hepatic encephalopathy", Am J Gastroenterol, 113, pp.1600~1612 (2018)
241. Hong SI, "Clinical observations of hepatic encephalopathy", J Korean Acad Fam Med, 12, pp.58~64 (1991)
242. 백용한, "Comparison of Rifaximin and Lactulose for the Treatment of Hepatic Encephalopathy: A Prospective Randomized Study", Yonsei Medical Journal, 46(3), pp.399~407 (2005), 연세대학교의과대학
243. Uribe M, "Acidifying enemas(lactitol and lactose)vs. nonacidifying enemas(tap water)to treat acute portal-systemic encephalopathy : a double-blind, randomized clinical trial", Hepatology, 7, pp.639~643 (1987)
244. Als-Nielsen B, "Nonabsorbable disaccharides for hepatic encephalopathy", Cochrane Database Syst Rev, (2), pp.CD003044~ (2004)
245. Gluud LL, "Nonabsorbable disaccharides for hepatic encephalopathy : a systematic review and meta-analysis", Hepatology, 64, pp.908~922 (2016)
246. Morgan MY, "Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients : a double-blind, randomized trial", Hepatology, 7, pp.1278~1284 (1987)
247. Kersh ES, "Lactulose enemas", Ann Intern Med, 78, pp.81~84 (1973)
248. Uribe M, "Lactose enemas plus placebo tablets vs. neomycin tablets plus starch enemas in acute portal systemic encephalopathy. A double-blind randomized controlled study", Gastroenterology, 81, pp.101~106 (1981)
249. Bucci L, "Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy", Curr Med Res Opin, 13, pp.109~118 (1993)
250. Patidar KR, "Antibiotics for the treatment of hepatic encephalopathy", Metab Brain Dis, 28, pp.307~312 (2013)
251. Mas A, "Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy : results of a randomized, double-blind, double-dummy, controlled clinical trial", J Hepatol, 38, pp.51~58 (2003)
252. Fera G, "Rifaximin in the treatment of hepatic encephalopathy", Eur J Clin Res, 4, pp.57~66 (1993)
253. Massa P, "Treatment of hepatic encephalopathy with rifaximin : double blind, double dummy study versus lactulose", Eur J Clin Res, 4, pp.7~18 (1993)
254. Kimer N, "Systematic review with meta-analysis : the effects of rifaximin in hepatic encephalopathy", Aliment Pharmacol Ther, 40, pp.123~132 (2014)
255. Sharma BC, "A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy", Am J Gastroenterol, 108, pp.1458~1463 (2013)
256. Phongsamran PV, "Pharmacotherapy for hepatic encephalopathy", Drugs, 70, pp.1131~1148 (2010)
257. Butterworth RF, "Efficacy of l-ornithine l-aspartate for the treatment of hepatic encephalopathy and hyperammonemia in cirrhosis : systematic review and meta-analysis of randomized controlled trials", J Clin Exp Hepatol, 8, pp.301~313 (2018)
258. Kircheis G, "Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy : results of a placebo-controlled, double-blind study", Hepatology, 25, pp.1351~1360 (1997)
259. Sidhu SS, "L-ornithine Laspartate in bouts of overt hepatic encephalopathy", Hepatology, 67, pp.700~710 (2018)
260. Stauch S, "Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy : results of a placebo-controlled double-blind study", J Hepatol, 28, pp.856~864 (1998)
261. Poo JL, "Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study", Ann Hepatol, 5, pp.281~288 (2006)
262. Song KH, "Prospective study on efficacy of oral supplement of branched-chain amino acid granules on the nutritional status of the cirrhotics", Korean J Hepatol, 7, pp.432~438 (2001)
263. Leise MD, "Management of hepatic encephalopathy in the hospital", Mayo Clin Proc, 89, pp.241~253 (2014)
264. Gluud LL, "Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy:what is the evidence?", Metab Brain Dis, 28, pp.221~225 (2013)
265. Gluud LL, "Oral branched-chain amino acids have a beneficial effect on manifestations of hepatic encephalopathy in a systematic review with meta-analyses of randomized controlled trials", J Nutr, 143, pp.1263~1268 (2013)
266. Gluud LL, "Branched-chain amino acids for people with hepatic encephalopathy", Cochrane Database Syst Rev, 5, pp.CD001939~ (2017)
267. Naylor CD, "Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy. A meta-analysis", Gastroenterology, 97, pp.1033~1042 (1989)
268. Sort P, "Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis", N Engl J Med, 341, pp.403~409 (1999)
269. Caraceni P, "Long-term albumin administration in decompensated cirrhosis(ANSWER) : an open-label randomised trial", Lancet, 391, pp.2417~2429 (2018)
270. Simón-Talero M, "Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy : a randomized double-blind study", J Hepatol, 59, pp.1184~1192 (2013)
271. Sharma BC, "Randomized controlled trial comparing lactulose plus albumin versus lactulose alone for treatment of hepatic encephalopathy", J Gastroenterol Hepatol, 32, pp.1234~1239 (2017)
272. Rahimi RS, "Lactulose vs polyethylene glycol 3350--electrolyte solution for treatment of overt hepatic encephalopathy : the HELP randomized clinical trial", JAMA Intern Med, 174, pp.1727~1733 (2014)
273. Goulenok C, "Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis : a meta-analysis", Aliment Pharmacol Ther, 16, pp.361~372 (2002)
274. Malaguarnera M, "Effects of L-carnitine in patients with hepatic encephalopathy", World J Gastroenterol, 11, pp.7197~7202 (2005)
275. Sushma S, "Sodium benzoate in the treatment of acute hepatic encephalopathy : a double-blind randomized trial", Hepatology, 16, pp.138~144 (1992)
276. Stewart CA, "Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease", Liver Transpl, 13, pp.1366~1371 (2007)
277. Bustamante J, "Prognostic significance of hepatic encephalopathy in patients with cirrhosis", J Hepatol, 30, pp.890~895 (1999)
278. Sharma BC, "Secondary prophylaxis of hepatic encephalopathy : an open-label randomized controlled trial of lactulose versus placebo", Gastroenterology, 137, pp.885~891 (2009)
279. Als-Nielsen B, "Non-absorbable disaccharides for hepatic encephalopathy : systematic review of randomised trials", BMJ, 328, pp.1046~ (2004)
280. Morgan MY, "Lactitol versus lactulose in the treatment of chronic hepatic encephalopathy. A double-blind, randomised, cross-over study", J Hepatol, 4, pp.236~244 (1987)
281. Vlachogiannakos J, "Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis", J Gastroenterol Hepatol, 28, pp.450~455 (2013)
282. Bass NM, "Rifaximin treatment in hepatic encephalopathy", N Engl J Med, 362, pp.1071~1081 (2010)
283. Mullen KD, "Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy", Clin Gastroenterol Hepatol, 12, pp.1390~1397.e2 (2014)
284. Kang SH, "Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy", Aliment Pharmacol Ther, 46, pp.845~855 (2017)
285. Neff GW, "Lack of Clostridium difficile infection in patients treated with rifaximin for hepatic encephalopathy : a retrospective analysis", J Clin Gastroenterol, 47, pp.188~192 (2013)
286. Park JG, "Effects of branched-chain amino acids (BCAAs) on the progression of advanced liver disease: a Korean nationwide, multicenter, retrospective, observational, cohort study", Medicine(Baltimore), 96, pp.e6580~ (2017)
287. Varakanahalli S, "Secondary prophylaxis of hepatic encephalopathy in cirrhosis of liver : a double-blind randomized controlled trial of L-ornithine L-aspartate versus placebo", Eur J Gastroenterol Hepatol, 30, pp.951~958 (2018)
288. Goh ET, "L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis", Cochrane Database Syst Rev, 5, pp.CD012410~ (2018)
289. Garrido M, "An educational tool for the prophylaxis of hepatic encephalopathy", BMJ Open Gastroenterol, 4, pp.e000161~ (2017)
290. Nardelli S, "Sarcopenia is risk factor for development of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt placement", Clin Gastroenterol Hepatol, 15, pp.934~936 (2017)
291. Lucero C, "The role of sarcopenia and frailty in hepatic encephalopathy management", Clin Liver Dis, 19, pp.507~528 (2015)
292. Hanai T, "Sarcopenia impairs prognosis of patients with liver cirrhosis", Nutrition, 31, pp.193~199 (2015)
293. Montano-Loza AJ, "Muscle wasting is associated with mortality in patients with cirrhosis", Clin Gastroenterol Hepatol, 10, pp.166~173 (2012)
294. Tandon P, "Severe muscle depletion in patients on the liver transplant wait list : its prevalence and independent prognostic value", Liver Transpl, 18, pp.1209~1216 (2012)
295. European Association of the Study of the Liver, "EASL clinical practice guidelines on nutrition in chronic liver disease", J Hepatol, 70, pp.172~193 (2019)
296. Tsien CD, "Late evening snack : exploiting a period of anabolic opportunity in cirrhosis", J Gastroenterol Hepatol, 27, pp.430~441 (2012)
297. Berzigotti A, "Physical activity and liver diseases", Hepatology, 63, pp.1026~1040 (2016)
298. García-Pagàn JC, "Physical exercise increases portal pressure in patients with cirrhosis and portal hypertension", Gastroenterology, 111, pp.1300~1306 (1996)
299. Qiu J, "Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-κB-mediated mechanism", Proc Natl Acad Sci U S A, 110, pp.18162~18167 (2013)
300. Nishikawa H, "Elevated serum myostatin level is associated with worse survival in patients with liver cirrhosis", J Cachexia Sarcopenia Muscle, 8, pp.915~925 (2017)
301. Román E, "Effects of an exercise programme on functional capacity, body composition and risk of falls in patients with cirrhosis : a randomized clinical trial", PLoS One, 11, pp.e0151652~ (2016)
302. Hartmann IJ, "The prognostic significance of subclinical hepatic encephalopathy", Am J Gastroenterol, 95, pp.2029~2034 (2000)
303. Saxena N, "Electrophysiological and neuropsychological tests for the diagnosis of subclinical hepatic encephalopathy and prediction of overt encephalopathy", Liver, 22, pp.190~197 (2002)
304. Prasad S, "Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy", Hepatology, 45, pp.549~559 (2007)
305. Sidhu SS, "Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy(the RIME trial)", Am J Gastroenterol, 106, pp.307~316 (2011)
306. Bajaj JS, "Inhibitory control test is a simple method to diagnose minimal hepatic encephalopathy and predict development of overt hepatic encephalopathy", Am J Gastroenterol, 102, pp.754~760 (2007)
307. Campagna F, "The animal naming test : an easy tool for the assessment of hepatic encephalopathy", Hepatology, 66, pp.198~208 (2017)
308. Maharshi S, "Efficacy of nutritional therapy for patients with cirrhosis and minimal hepatic encephalopathy in a randomized trial", Clin Gastroenterol Hepatol, 14, pp.454~460.e3 (2016)
309. Dhiman RK, "Diagnosis and prognostic significance of minimal hepatic encephalopathy in patients with cirrhosis of liver", Dig Dis Sci, 55, pp.2381~2390 (2010)
310. Seo YS, "Psychometric hepatic encephalopathy score for the detection of minimal hepatic encephalopathy in Korean patients with liver cirrhosis", J Gastroenterol Hepatol, 27, pp.1695~1704 (2012)
311. Patidar KR, "Covert and overt hepatic encephalopathy : diagnosis and management", Clin Gastroenterol Hepatol, 13, pp.2048~2061 (2015)
312. Groeneweg M, "Subclinical hepatic encephalopathy impairs daily functioning", Hepatology, 28, pp.45~49 (1998)
313. Román E, "Minimal hepatic encephalopathy is associated with falls", Am J Gastroenterol, 106, pp.476~482 (2011)
314. Soriano G, "Cognitive dysfunction in cirrhosis is associated with falls : a prospective study", Hepatology, 55, pp.1922~1930 (2012)
315. Bajaj JS, "The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers", Am J Gastroenterol, 106, pp.1646~1653 (2011)
316. Ampuero J, "Minimal hepatic encephalopathy and critical flicker frequency are associated with survival of patients with cirrhosis", Gastroenterology, 149, pp.1483~1489 (2015)
317. Patidar KR, "Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization", Am J Gastroenterol, 109, pp.1757~1763 (2014)
318. Schomerus H, "Neuropsychological aspects of portalsystemic encephalopathy", Metab Brain Dis, 13, pp.361~377 (1998)
319. Weissenborn K, "Neuropsychological characterization of hepatic encephalopathy", J Hepatol, 34, pp.768~773 (2001)
320. Amodio P, "Detection of minimal hepatic encephalopathy : normalization and optimization of the Psychometric Hepatic Encephalopathy Score. A neuropsychological and quantified EEG study", J Hepatol, 49, pp.346~353 (2008)
321. Badea MA, "Diagnosis of minimal hepatic encephalopathy in a tertiary care center from eastern Romania : validation of the psychometric hepatic encephalopathy score(PHES)", Metab Brain Dis, 31, pp.1463~1471 (2016)
322. Duarte-Rojo A, "Validation of the psychometric hepatic encephalopathy score(PHES)for identifying patients with minimal hepatic encephalopathy", Dig Dis Sci, 56, pp.3014~3023 (2011)
323. Li SW, "Psychometric hepatic encephalopathy score for diagnosis of minimal hepatic encephalopathy in China", World J Gastroenterol, 19, pp.8745~8751 (2013)
324. Romero-Gómez M, "Value of the critical flicker frequency in patients with minimal hepatic encephalopathy", Hepatology, 45, pp.879~885 (2007)
325. 정재윤, "Validation of a Paper and Pencil Test Battery for the Diagnosis of Minimal Hepatic Encephalopathy in Korea", Journal of Korean Medical Science, 32(9), pp.1484~1490 (2017), 대한의학회
326. "Integrated diagnostic website for covert hepatic encephalopathy"[URL]
327. Bajaj JS, "Inhibitory control test for the diagnosis of minimal hepatic encephalopathy", Gastroenterology, 135, pp.1591~1600.e1 (2008)
328. Bajaj JS, "The stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy", Hepatology, 58, pp.1122~1132 (2013)
329. Bajaj JS, "Validation of encephalApp, smartphone-based stroop test, for the diagnosis of covert hepatic encephalopathy", Clin Gastroenterol Hepatol, 13, pp.1828~1835.e1 (2015)
330. Allampati S, "Diagnosis of minimal hepatic encephalopathy using stroop encephalApp : a multicenter US-based, Norm-based study", Am J Gastroenterol, 111, pp.78~86 (2016)
331. Yoon EL, "Validation of Korean stroop test in the screening of minimal hepatic encephalopathy", Sci Rep, 9, pp.8027~ (2019)
332. Guerit JM, "Neurophysiological investigations of hepatic encephalopathy : ISHEN practice guidelines", Liver Int, 29, pp.789~796 (2009)
333. Kircheis G, "Critical flicker frequency for quantification of low-grade hepatic encephalopathy", Hepatology, 35, pp.357~366 (2002)
334. Torlot FJ, "Meta-analysis : the diagnostic accuracy of critical flicker frequency in minimal hepatic encephalopathy", Aliment Pharmacol Ther, 37, pp.527~536 (2013)
335. Labenz C, "Validation of the simplified Animal Naming Test as primary screening tool for the diagnosis of covert hepatic encephalopathy", Eur J Intern Med, 60, pp.96~100 (2019)
336. Nabi E, "Diagnosis of covert hepatic encephalopathy without specialized tests", Clin Gastroenterol Hepatol, 12, pp.1384~1389.e2 (2014)
337. Li W, "Interferon gamma, interleukin-6, and-17a levels were correlated with minimal hepatic encephalopathy in HBV patients", Hepatol Int, 9, pp.218~223 (2015)
338. Montoliu C, "IL-6 and IL-18 in blood may discriminate cirrhotic patients with and without minimal hepatic encephalopathy", J Clin Gastroenterol, 43, pp.272~279 (2009)
339. Wu H, "Cytokine levels contribute to the pathogenesis of minimal hepatic encephalopathy in patients with hepatocellular carcinoma via STAT3 activation", Sci Rep, 6, pp.18528~ (2016)
340. Felipo V, "Serum nitrotyrosine and psychometric tests as indicators of impaired fitness to drive in cirrhotic patients with minimal hepatic encephalopathy", Liver Int, 33, pp.1478~1489 (2013)
341. Montoliu C, "3-nitro-tyrosine as a peripheral biomarker of minimal hepatic encephalopathy in patients with liver cirrhosis", Am J Gastroenterol, 106, pp.1629~1637 (2011)
342. Montagnese S, "Covert hepatic encephalopathy : agreement and predictive validity of different indices", World J Gastroenterol, 20, pp.15756~15762 (2014)
343. Montagnese S, "Different biochemical correlates for different neuropsychiatric abnormalities in patients with cirrhosis", Hepatology, 53, pp.558~566 (2011)
344. Henderson PK, "Should we treat minimal", covert hepatic encephalopathy, and with what?, 2015, pp.19, 487~495
345. Luo M, "Clinical efficacy and safety of lactulose for minimal hepatic encephalopathy : a meta-analysis", Eur J Gastroenterol Hepatol, 23, pp.1250~1257 (2011)
346. Bajaj JS, "Probiotic yogurt for the treatment of minimal hepatic encephalopathy", Am J Gastroenterol, 103, pp.1707~1715 (2008)
347. Liu Q, "Synbiotic modulation of gut flora : effect on minimal hepatic encephalopathy in patients with cirrhosis", Hepatology, 39, pp.1441~1449 (2004)
348. Saab S, "Probiotics are helpful in hepatic encephalopathy : a meta-analysis of randomized trials", Liver Int, 36, pp.986~993 (2016)
349. Viramontes Hörner D, "The effects of probiotics and symbiotics on risk factors for hepatic encephalopathy : a systematic review", J Clin Gastroenterol, 51, pp.312~323 (2017)
350. Bajaj JS, "Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents : a cost-effectiveness analysis", Hepatology, 55, pp.1164~1171 (2012)
351. Sidhu SS, "Rifaximin vs. lactulose in treatment of minimal hepatic encephalopathy", Liver Int, 36, pp.378~385 (2016)
352. Mittal VV, "A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy", Eur J Gastroenterol Hepatol, 23, pp.725~732 (2011)
353. Les I, "Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy : a randomized study", Am J Gastroenterol, 106, pp.1081~1088 (2011)
354. Malaguarnera M, "Acetyl-L-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathy", Scand J Gastroenterol, 46, pp.750~759 (2011)
355. Malaguarnera M, "Acetyl-L-carnitine treatment in minimal hepatic encephalopathy", Dig Dis Sci, 53, pp.3018~3025 (2008)
356. Younossi ZM, "Health-related quality of life in chronic liver disease : the impact of type and severity of disease", Am J Gastroenterol, 96, pp.2199~2205 (2001)
357. Arguedas MR, "Influence of hepatic encephalopathy on health-related quality of life in patients with cirrhosis", Dig Dis Sci, 48, pp.1622~1626 (2003)
358. Ries ML, "Anosognosia in mild cognitive impairment : relationship to activation of cortical midline structures involved in selfappraisal", J Int Neuropsychol Soc, 13, pp.450~461 (2007)
359. Bao ZJ, "Assessment of health-related quality of life in Chinese patients with minimal hepatic encephalopathy", World J Gastroenterol, 13, pp.3003~3008 (2007)
360. Les I, "Quality of life in cirrhosis is related to potentially treatable factors", Eur J Gastroenterol Hepatol, 22, pp.221~227 (2010)
361. Schomerus H, "Quality of life in cirrhotics with minimal hepatic encephalopathy", Metab Brain Dis, 16, pp.37~41 (2001)
362. Wunsch E, "Minimal hepatic encephalopathy does not impair healthrelated quality of life in patients with cirrhosis : a prospective study", Liver Int, 31, pp.980~984 (2011)
363. Patrick DL, "Generic and disease-specific measures in assessing health status and quality of life", Med Care, 27, pp.S217~S232 (1989)
364. Garratt A, "Quality of life measurement : bibliographic study of patient assessed health outcome measures", BMJ, 324, pp.1417~ (2002)
365. Bergner M, "The sickness impact profile : development and final revision of a health status measure", Med Care, 19, pp.787~805 (1981)
366. Hunt SM, "Measuring health status : a new tool for clinicians and epidemiologists", J R Coll Gen Pract, 35, pp.185~188 (1985)
367. Brazier J, "The estimation of a preference-based measure of health from the SF-36", J Health Econ, 21, pp.271~292 (2002)
368. Younossi ZM, "Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease", Gut, 45, pp.295~300 (1999)
369. Gralnek IM, "Development and evaluation of the Liver Disease Quality of Life instrument in persons with advanced, chronic liver disease--the LDQOL 1. 0", Am J Gastroenterol, 95, pp.3552~3565 (2000)
370. Kanwal F, "Prospective validation of the short form liver disease quality of life instrument", Aliment Pharmacol Ther, 28, pp.1088~1101 (2008)
371. van der Plas SM, "The liver disease symptom index 2. 0; validation of a disease-specific questionnaire", Qual Life Res, 13, pp.1469~1481 (2004)
372. Mullen KD, "Review of the final report of the 1998 Working Party on definition, nomenclature and diagnosis of hepatic encephalopathy", Aliment Pharmacol Ther, 25(Suppl 1), pp.11~16 (2007)
373. Ortiz M, "Minimal hepatic encephalopathy:diagnosis, clinical significance and recommendations", J Hepatol, 42(Suppl), pp.S45~S53 (2005)
374. Moscucci F, "Previous overt hepatic encephalopathy rather than minimal hepatic encephalopathy impairs health-related quality of life in cirrhotic patients", Liver Int, 31, pp.1505~1510 (2011)
375. Bajaj JS, "Deleterious effect of cirrhosis on outcomes after motor vehicle crashes using the nationwide inpatient sample", Am J Gastroenterol, 103, pp.1674~1681 (2008)
376. Bajaj JS, "Minimal hepatic encephalopathy : a vehicle for accidents and traffic violations", Am J Gastroenterol, 102, pp.1903~1909 (2007)
377. Marottoli RA, "Predictors of automobile crashes and moving violations among elderly drivers", Ann Intern Med, 121, pp.842~846 (1994)
378. Wein C, "Minimal hepatic encephalopathy impairs fitness to drive", Hepatology, 39, pp.739~745 (2004)
379. Martino ME, "Sleep electroencephalogram alterations disclose initial stage of encephalopathy", Methods Find Exp Clin Pharmacol, 24(Suppl D), pp.119~122 (2002)
380. Bianchi G, "Psychological status and depression in patients with liver cirrhosis", Dig Liver Dis, 37, pp.593~600 (2005)
381. Mostacci B, "Sleep disturbance and daytime sleepiness in patients with cirrhosis : a case control study", Neurol Sci, 29, pp.237~240 (2008)
382. Wells KB, "The functioning and well-being of depressed patients. Results from the Medical Outcomes Study", JAMA, 262, pp.914~919 (1989)
383. Marchesini G, "Factors associated with poor health-related quality of life of patients with cirrhosis", Gastroenterology, 120, pp.170~178 (2001)
384. Sanyal A, "Randomised clinical trial : rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy-a double-blind placebo-controlled study", Aliment Pharmacol Ther, 34, pp.853~861 (2011)
385. Ong JP, "Oral L-ornithine-L-aspartate improves health-related quality of life in cirrhotic patients with hepatic encephalopathy : an openlabel, prospective, multicentre observational study", Clin Drug Investig, 31, pp.213~220 (2011)
386. Davies MG, "EEG and event related potentials in hepatic encephalopathy", Metab Brain Dis, 6, pp.175~186 (1991)

관련 논문AI추천